BioMarin Pharmaceutical vs Bio-Techne
BioMarin Pharmaceutical (BMRN), health care, and Bio-Techne (TECH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
BioMarin Pharmaceutical and Bio-Techne are valued at about the same: $11.3B and $11.4B. BioMarin Pharmaceutical's operating margin in its latest fiscal year was 12.7% and Bio-Techne's 20.7%. Over the past year BioMarin Pharmaceutical's share price has moved +7.07% and Bio-Techne's +25.2%.
Key facts
- BioMarin Pharmaceutical market value
- $11.3B
- Bio-Techne market value
- $11.4B
- Bio-Techne P/E
- 66.7
- BioMarin Pharmaceutical revenue
- $3.2BFY to 2025-12-31
- Bio-Techne revenue
- $1.2BFY to 2026-06-30
- Superinvestors holding both
- 0
Market values as of .
| Measure | BioMarin Pharmaceutical | Bio-Techne |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-06-30 |
| Size | ||
| Market cap | $11.3Blower | $11.4Bhigher |
| Revenue | $3.2Bhigher | $1.2Blower |
| Earnings | $348.9Mhigher | $181.9Mlower |
| Employees | 3,221higher | 3,000lower |
| Total assets | $7.6Bhigher | $2.6Blower |
| Valuation | ||
| P/E | — | 66.7 |
| P/S | 3.5lower | 9.4higher |
| P/B | 1.8lower | 5.3higher |
| Dividend yield | 0.00%lower | 0.33%higher |
| Profitability | ||
| Operating margin | 12.7%lower | 20.7%higher |
| Balance sheet | ||
| Net assets | $6.1Bhigher | $2.1Blower |
| Total liabilities | $1.5Bhigher | $478.5Mlower |
| Total debt | — | $200M |
| Cash on hand | $1.3Bhigher | $264.7Mlower |
| Price change | ||
| Today | +0.76%higher | -0.06%lower |
| 1 year | +7.07%lower | +25.2%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
BioMarin Pharmaceutical only (3)
- Andreas Halvorsen1.2%
- Primecap team0.6%
- Dodge & Cox team0.5%
Bio-Techne only (7)
- Sequoia Fund team3.9%
- Wallace Weitz1.3%
- Lee Ainslie1.0%
- Mairs & Power team0.8%
- Henry Ellenbogen0.3%
- Paul Tudor Jones0.3%
- Larry Robbins0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns BMRN · Who owns TECH
More on BioMarin Pharmaceutical
Further comparisons
BioMarin Pharmaceutical against its closest peers
Bio-Techne against its closest peers
Learn
Questions and answers
Which is bigger, BioMarin Pharmaceutical or Bio-Techne?
By market value, Bio-Techne is the larger: $11.4B against $11.3B for BioMarin Pharmaceutical. By revenue in its latest fiscal year, BioMarin Pharmaceutical is the larger: $3.2B against $1.2B for Bio-Techne.
Which has the higher operating margin?
Bio-Techne: 20.7%, against 12.7% for BioMarin Pharmaceutical. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Bio-Techne: 0.33%, against 0.00% for BioMarin Pharmaceutical. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both BioMarin Pharmaceutical and Bio-Techne?
None of the tracked superinvestors holds both in their latest 13F filing. 3 hold BioMarin Pharmaceutical and 7 hold Bio-Techne.
Cite this page
Funkfolio, “BioMarin Pharmaceutical vs Bio-Techne”, data as of 17 November 2026. https://funkfolio.com/compare/bmrn-vs-tech
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.